A synonymous coding polymorphism in the α2-Heremans-Schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians

被引:68
作者
Siddiq, A
Lepretre, F
Hercberg, S
Froguel, P
Gibson, F
机构
[1] Univ London Imperial Coll Sci & Technol, Med Genet Sect, London W12 0NN, England
[2] CHU Lille, Inst Pasteur, Inst Biol Lille, F-59037 Lille, France
[3] Conservatoire Natl Arts & Metiers, Inst Sci & Tech Nutr & Alimentat, INSERM, U557,InVS, F-75003 Paris, France
[4] Conservatoire Natl Arts & Metiers, Inst Sci & Tech Nutr & Alimentat, Unite Surveillance & Epidemiol Nutr, F-75003 Paris, France
基金
英国医学研究理事会; 英国惠康基金;
关键词
D O I
10.2337/diabetes.54.8.2477
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
alpha 2-Heremans-Schmid glycoprotein (AHSG) is an abundant plasma protein synthesized predominantly in the liver. The AHSG gene, consisting of seven exons and spanning 8.2 kb of genomic DNA, is located at chromosome 3q27, a susceptibility locus for type 2 diabetes and the metabolic syndrome. A_HSG is a natural inhibitor of the insulin receptor tyrosine kinase, and AHSG-null mice exhibit significantly enhanced insulin sensitivity. These observations suggested that the A_HSG gene is a strong positional and biological candidate for type 2 diabetes susceptibility. Direct sequencing of the AHSG promoter region and exons identified nine common single nucleotide polymorphisms (SNPs) with a minor allele frequency 5 %. We carried out a detailed genetic association study of the contribution of these common AHSG SNPs to genetic susceptibility of type 2 diabetes in French Caucasians. The major allele of a synonymous coding SNP in exon 7 (rs1071592) presented significant evidence of association with type 2 diabetes (P = 0.008, odds ratio 1.27 [95 % Cl 1.06-1.52]). Two other SNPs (rs2248690 and rs4918) in strong linkage disequilibrium with rs1071592 showed evidence approaching significance. A haplotype carrying the minor allele of SNP rs1071592 was protective against type 2 diabetes (P = 0.014). However, our analyses indicated that rs1071592 is not associated with the evidence for linkage of type 2 diabetes to 3q27.
引用
收藏
页码:2477 / 2481
页数:5
相关论文
共 25 条
[1]   GOLD - Graphical Overview of Linkage Disequilibrium [J].
Abecasis, GR ;
Cookson, WOC .
BIOINFORMATICS, 2000, 16 (02) :182-183
[2]   CHARACTERIZATION OF A NATURAL INHIBITOR OF THE INSULIN-RECEPTOR TYROSINE KINASE - CDNA CLONING, PURIFICATION, AND ANTI-MITOGENIC ACTIVITY [J].
AUBERGER, P ;
FALQUERHO, L ;
CONTRERES, JO ;
PAGES, G ;
LECAM, G ;
ROSSI, B ;
LECAM, A .
CELL, 1989, 58 (04) :631-640
[3]   GAD2 on chromosome 10p12 is a candidate gene for human obesity [J].
Boutin, P ;
Dina, C ;
Vasseur, F ;
Dubois, S ;
Corset, L ;
Séron, K ;
Bekris, L ;
Cabellon, J ;
Neve, B ;
Vasseur-Delannoy, V ;
Chikri, M ;
Charles, MA ;
Clement, K ;
Lernmark, A ;
Froguel, P .
PLOS BIOLOGY, 2003, 1 (03) :361-371
[4]   α2-Heremans-Schmid glycoprotein gene polymorphisms are associated with adipocyte insulin action [J].
Dahlman, I ;
Eriksson, P ;
Kaaman, M ;
Jiao, H ;
Lindgren, CM ;
Kere, J ;
Arner, P .
DIABETOLOGIA, 2004, 47 (11) :1974-1979
[5]   Base-calling of automated sequencer traces using phred.: I.: Accuracy assessment [J].
Ewing, B ;
Hillier, L ;
Wendl, MC ;
Green, P .
GENOME RESEARCH, 1998, 8 (03) :175-185
[6]   A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27 [J].
Francke, S ;
Manraj, M ;
Lacquemant, C ;
Lecoeur, C ;
Leprêtre, F ;
Passa, P ;
Hebe, A ;
Corset, L ;
Yan, SLK ;
Lahmidi, S ;
Jankee, S ;
Gunness, TK ;
Ramjuttun, US ;
Balgobin, V ;
Dina, C ;
Froguel, P .
HUMAN MOLECULAR GENETICS, 2001, 10 (24) :2751-2765
[7]  
Gavin JR, 1999, DIABETES CARE, V22, pS5
[8]   Genetics of the APM1 locus and its contribution to type 2 diabetes susceptibility in French Caucasians [J].
Gibson, F ;
Froguel, P .
DIABETES, 2004, 53 (11) :2977-2983
[9]   Consed: A graphical tool for sequence finishing [J].
Gordon, D ;
Abajian, C ;
Green, P .
GENOME RESEARCH, 1998, 8 (03) :195-202
[10]   A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: The SU.VI.MAX study - Design, methods, and participant characteristics [J].
Hercberg, S ;
Preziosi, P ;
Briancon, S ;
Galan, P ;
Triol, I ;
Malvy, D ;
Roussel, AM ;
Favier, A .
CONTROLLED CLINICAL TRIALS, 1998, 19 (04) :336-351